SG11201407416XA - Use of semaphorin-4d binding molecules to promote neurogenesis following stroke - Google Patents
Use of semaphorin-4d binding molecules to promote neurogenesis following strokeInfo
- Publication number
- SG11201407416XA SG11201407416XA SG11201407416XA SG11201407416XA SG11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA
- Authority
- SG
- Singapore
- Prior art keywords
- semaphorin
- binding molecules
- following stroke
- promote neurogenesis
- neurogenesis following
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646119P | 2012-05-11 | 2012-05-11 | |
| US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| PCT/US2013/040661 WO2013170221A1 (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407416XA true SG11201407416XA (en) | 2015-03-30 |
Family
ID=49548777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407416XA SG11201407416XA (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10494440B2 (es) |
| EP (1) | EP2846831B1 (es) |
| JP (1) | JP6218810B2 (es) |
| KR (1) | KR102105436B1 (es) |
| CN (2) | CN104619341A (es) |
| AU (1) | AU2013259192B2 (es) |
| BR (1) | BR112014028160B1 (es) |
| CA (1) | CA2872928C (es) |
| DK (1) | DK2846831T3 (es) |
| EA (1) | EA030796B1 (es) |
| ES (1) | ES2882881T3 (es) |
| IL (1) | IL235603B (es) |
| MX (1) | MX358991B (es) |
| NZ (1) | NZ630864A (es) |
| PT (1) | PT2846831T (es) |
| SG (1) | SG11201407416XA (es) |
| WO (1) | WO2013170221A1 (es) |
| ZA (1) | ZA201501674B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| MX2018012818A (es) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus. |
| IL264343B2 (en) | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells |
| SG11201906670PA (en) * | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | 4D ANTI-SEMAPHORIN HUMAN ANTIBODY |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| AU6897998A (en) | 1997-04-11 | 1998-11-11 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-rela ted antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| DE69839970D1 (de) | 1998-11-10 | 2008-10-16 | Univ Rochester | Methoden zu herstellung von genbanken |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| DE60233509D1 (de) | 2001-06-20 | 2009-10-08 | Fibron Ltd | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| CA2526085A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| EP2336178A1 (en) | 2003-12-11 | 2011-06-22 | Genentech, Inc. | Methods and compositions for inhibiting C-Met dimerization and activation |
| AU2005209331A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| WO2006007539A1 (en) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
| DK1773885T3 (da) | 2004-08-05 | 2010-08-16 | Genentech Inc | Humaniserede anti-c-met-antagonister |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| TW200934512A (en) | 2008-01-10 | 2009-08-16 | Genentech Inc | PLEXIND1 agonists and their use |
| CN102421913A (zh) * | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗ｃｄ１００抗体およびこれを使用するための方法 |
| JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | ワクチン免疫療法 |
| AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| JP5925768B2 (ja) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | 骨形成促進剤 |
| SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| SG11201906670PA (en) * | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/en active Active
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt active IP Right Grant
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/en active Application Filing
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active IP Right Grant
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en active Active
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en unknown
- 2013-05-10 CA CA2872928A patent/CA2872928C/en active Active
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX358991B (es) | 2018-08-31 |
| JP6218810B2 (ja) | 2017-10-25 |
| US20130302320A1 (en) | 2013-11-14 |
| DK2846831T3 (en) | 2021-10-11 |
| JP2015517502A (ja) | 2015-06-22 |
| CN104619341A (zh) | 2015-05-13 |
| IL235603A0 (en) | 2015-01-29 |
| CN110064054A (zh) | 2019-07-30 |
| WO2013170221A1 (en) | 2013-11-14 |
| CA2872928A1 (en) | 2013-11-14 |
| CA2872928C (en) | 2021-02-16 |
| NZ630864A (en) | 2017-03-31 |
| AU2013259192B2 (en) | 2018-02-22 |
| BR112014028160B1 (pt) | 2021-01-12 |
| EP2846831B1 (en) | 2021-07-07 |
| AU2013259192A1 (en) | 2014-11-27 |
| EP2846831A1 (en) | 2015-03-18 |
| KR20150018555A (ko) | 2015-02-23 |
| MX2014013676A (es) | 2015-02-05 |
| ZA201501674B (en) | 2021-06-30 |
| EA030796B1 (ru) | 2018-09-28 |
| PT2846831T (pt) | 2021-08-19 |
| IL235603B (en) | 2020-01-30 |
| ES2882881T3 (es) | 2021-12-03 |
| KR102105436B1 (ko) | 2020-04-29 |
| US10494440B2 (en) | 2019-12-03 |
| EA201492067A1 (ru) | 2015-05-29 |
| EP2846831A4 (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501674B (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| EP2932375A4 (en) | ADAPTATION OF OPPORTUNITY IN CONTEXT | |
| AP2015008266A0 (en) | 1L-18 binding molecules | |
| IL234234B (en) | 2ang binding molecules | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| GB201303603D0 (en) | Improvements relating to valves | |
| AP2013007086A0 (en) | Bispecific binding molecules binding to DII4 and Ang2 | |
| EP2881113A4 (en) | NEW APPLICATION OF POGOSTONE | |
| EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
| GB2505689B (en) | Improvements to valve assemblies | |
| HK1199410A1 (en) | Composition for enhancing defenses of skin | |
| IL229958B (en) | Improvements to pumps and components therefor | |
| EP2926078A4 (en) | IMPROVEMENTS IN PATRIDGE VISION SYSTEMS AND RELATED METHODS | |
| GB201215007D0 (en) | Improvements in or relating to luminaires | |
| GB2507762B (en) | Improvements to dartboards | |
| GB201220796D0 (en) | Improvements relating to authentication | |
| GB201215288D0 (en) | Improvements relating to firelighters | |
| GB201222774D0 (en) | Improvements relating to aution mechanisms | |
| GB201222657D0 (en) | Improvements relating to personal tracking identifiers | |
| GB201204924D0 (en) | Improvements relating to splitting devices | |
| GB201209623D0 (en) | Improvements relating to mobile technology | |
| GB201208097D0 (en) | Improvements relating to mobile technology | |
| GB201213079D0 (en) | Novel use of aggregates |